Cargando…
Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515457/ https://www.ncbi.nlm.nih.gov/pubmed/34645676 http://dx.doi.org/10.1136/jitc-2020-001701corr1 |
| _version_ | 1784583614358355968 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8515457 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85154572021-10-27 Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany J Immunother Cancer Correction BMJ Publishing Group 2021-10-13 /pmc/articles/PMC8515457/ /pubmed/34645676 http://dx.doi.org/10.1136/jitc-2020-001701corr1 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany |
| title | Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany |
| title_full | Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany |
| title_fullStr | Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany |
| title_full_unstemmed | Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany |
| title_short | Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany |
| title_sort | correction: real-life use of talimogene laherparepvec (t-vec) in melanoma patients in centers in austria, switzerland and germany |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515457/ https://www.ncbi.nlm.nih.gov/pubmed/34645676 http://dx.doi.org/10.1136/jitc-2020-001701corr1 |